Celyad Oncology (XBRU:CYAD) Other Long Term Assets : €2.99 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Other Long Term Assets?

Celyad Oncology's other long-term assets for the quarter that ended in Jun. 2023 was €2.99 Mil.

Celyad Oncology's quarterly other long-term assets declined from Jun. 2022 (€4.32 Mil) to Dec. 2022 (€3.72 Mil) but then stayed the same from Dec. 2022 (€3.72 Mil) to Jun. 2023 (€2.99 Mil).

Celyad Oncology's annual other long-term assets increased from Dec. 2020 (€6.09 Mil) to Dec. 2021 (€6.24 Mil) but then declined from Dec. 2021 (€6.24 Mil) to Dec. 2022 (€3.72 Mil).

Celyad Oncology Other Long Term Assets Historical Data

The historical data trend for Celyad Oncology's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Other Long Term Assets Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long Term Assets

Get a 7-Day Free Trial

3.43

5.74

6.09

6.24

3.72

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Other Long Term Assets	Get a 7-Day Free Trial															6.24	4.15	4.32	3.72	2.99

Celyad Oncology Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Celyad Oncology (XBRU:CYAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

1C0:Germany

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines